2025-10-20 - Analysis Report
Okay, here's a comprehensive analysis of TransMedics Group Inc. (TMDX), incorporating all the provided data points.

**Report on TransMedics Group Inc. (TMDX)**

**1. Performance vs. S&P 500 (VOO)**

*   **Ticker:** TMDX
*   **Company Overview:** TransMedics Group Inc. is a medical technology company focused on developing and delivering innovative ex-vivo organ perfusion and assessment systems for organ transplantation.
*   **TMDX Cumulative Return:** 194.63%
*   **VOO (S&P 500) Cumulative Return:** 72.29%
*   **Absolute Divergence:** 122.3 (max: 247.2, min: -74.5)
*   **Relative Divergence:** 61.2

**Analysis:** TMDX has significantly outperformed the S&P 500. The relative divergence of 61.2 indicates that TMDX's outperformance is positioned well within its historical range, suggesting a potentially sustainable trend.

**Alpha, Beta Analysis**

| Year       |   CAGR |   MDD |   Alpha |   Beta |   Cap(B) |
|:-----------|-------:|------:|--------:|-------:|---------:|
| 2019-2021  | -18.0% | 83.5% | -61.0%  |   -0.0 |      0.7 |
| 2020-2022  |  94.0% | 83.5% |  95.0%  |    0.0 |      2.1 |
| 2021-2023  |  65.0% | 80.5% |  64.0%  |    0.1 |      2.7 |
| 2022-2024  | 130.0% | 85.5% | 109.0%  |    0.1 |      2.1 |
| 2023-2025  | 115.0% | 85.5% |  54.0%  |    0.3 |      4.0 |

*   **CAGR:** High growth rates in recent periods (2020-2025).
*   **MDD:** Consistently high Maximum Drawdown values suggest significant volatility.
*   **Alpha:** High Alpha values indicate significant outperformance relative to the market.
*   **Beta:** Beta values close to zero suggest that the stock price is relatively independent of market fluctuations.
*   **Cap:** The market capitalization has increased significantly, reflecting strong growth.

**2. Recent Price Action**

*   **Current Price:** \$117.63
*   **Previous Close:** \$115.68
*   **Change:** 1.69%
*   **5-day Moving Average:** 113.77
*   **20-day Moving Average:** 114.52
*   **60-day Moving Average:** 116.15

**Analysis:** The current price is above all three moving averages, suggesting an upward trend.  The 1.69% increase relative to the previous close reinforces this bullish sentiment, hinting at positive market reaction to recent news or events.

**3. Technical Indicators and Expected Return**

*   **Market Risk Indicator (MRI):** 0.5 (Low Investment Risk)
*   **RSI:** 57.55 (Neutral)
*   **PPO:** 0.2694
*   **Hybrid Signal:** Buy 100% (Very Safe)
*   **Delta_Previous_Relative_Divergence (20-day):** 7.1 (+) (Short-term Increase)
*   **Expected Return:** 49.6% (Long-term)

**Analysis:**

*   The MRI indicates a low investment risk, a positive sign.
*   The RSI suggests a neutral market sentiment.
*   The positive change in relative divergence suggests improving momentum.
*   The expected return of 49.6% indicates significant potential upside over the long term.

**4. Recent News & Significant Events**

*   **Jefferies Initiates TransMedics Group at Buy With $145 Price Target:** This suggests analyst confidence.
*   **TransMedics Group Stock Earns Relative Strength Rating Upgrade:** Positive momentum is recognized.
*   **Earnings Report Scheduled (Oct 29):** An important event to watch.
*   **Coverage in Motley Fool & Zacks:** Highlights positive growth outlook.

**Analysis:** Recent news is overwhelmingly positive, with analyst upgrades, strong growth stock recognition, and favorable outlooks.

**4.2 Analyst Opinions**

*   **Consensus:** Buy
*   **Mean Rating:** 1.75 (~Buy)
*   **Opinions:** 10
*   **Target Price (Avg/High/Low):** \$141.00 / \$170.00 / \$114.00

**Analysis:** Strong analyst consensus indicates a positive outlook on the stock, with an average target price significantly higher than the current price.

**5. Recent Earnings Analysis**

| Date       |   EPS |   Expected EPS |
|:-----------|------:|---------------:|
| 2025-07-30 |  0.92 |           0.48 |
| 2025-05-08 |  0.7  |           0.29 |
| 2025-02-27 |  0.19 |           0.22 |
| 2024-10-28 |  0.12 |           0.29 |
| 2024-07-31 |  0.35 |           0.21 |

**Analysis:**  TransMedics has consistently exceeded EPS expectations in recent quarters, signaling strong financial performance and positive growth trends. In particular, 2025-07-30 and 2025-05-08 show significantly higher EPS compared to expectations, indicating a positive trend.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter    |   Revenue |   Profit Margin |
|:-----------|----------:|----------------:|
| 2025-06-30 |     0.16B |           61.38% |
| 2025-03-31 |     0.14B |           61.47% |
| 2024-12-31 |     0.12B |           59.21% |
| 2024-09-30 |     0.11B |           55.94% |
| 2024-06-30 |     0.11B |           60.59% |

**Capital and Profitability:**

| Quarter    |   Equity |    ROE |
|:-----------|---------:|-------:|
| 2025-06-30 |    0.32B | 10.97% |
| 2025-03-31 |    0.27B |  9.64% |
| 2024-12-31 |    0.23B |  3.00% |
| 2024-09-30 |    0.21B |  2.01% |
| 2024-06-30 |    0.19B |  6.42% |

**Analysis:**

*   **Revenue:** Demonstrates consistent quarter-over-quarter growth.
*   **Profit Margin:**  Very high and relatively stable, indicating strong operational efficiency.
*   **Equity:**  Increasing steadily, indicating a strengthening financial position.
*   **ROE:** Increasing trend, indicating improved profitability relative to equity.

**7. Overall Summary**

TransMedics Group Inc. (TMDX) presents a compelling investment case based on the provided data:

*   **Strong Performance:**  Significant outperformance vs. the S&P 500.
*   **Positive Momentum:**  Upward price trend, positive news flow, and increasing relative divergence.
*   **Strong Financials:** Growing revenue, high profit margins, and increasing equity and ROE.
*   **Analyst Confidence:**  Buy consensus with a target price significantly above the current level.
*   **Potential Risks:**  High MDD values indicate significant volatility.

**Conclusion:**  Based on the data, TMDX appears to be a strong growth stock with significant potential upside. While the high volatility should be considered, the positive fundamentals, analyst support, and strong financial performance suggest a favorable outlook.
